HPβCD Adjuvant Therapy for Cholesterol-Driven EMT Reversal

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments face challenges with metastasis and drug resistance, particularly due to cholesterol-mediated EMT, which leads to increased drug resistance and poor survival rates, and existing cholesterol-lowering agents like statins have debilitating side effects.

Innovation Solution

Utilizing 2-hydroxypropyl-β-cyclodextrin (HPβCD) as a neoadjuvant or adjuvant therapy to target cellular cholesterol, reversing the EMT phenotype, enhancing sensitivity to cancer therapies, and reducing toxicity and side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If statins are used to lower cellular cholesterol to reverse EMT and enhance drug sensitivity, then cancer therapy sensitivity is improved, but debilitating side effects occur including muscle pains, hepato- and renal-toxicity, neurocognitive decline, myopathy, and idiopathic polyneuropathy

Engineering Contradiction:

Improvecancer therapy sensitivityVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs HPβCD, a cyclodextrin derivative, as a temporary cholesterol-depleting agent that achieves the desired therapeutic effect without the long-term toxicity of statins. HPβCD forms inclusion complexes with cholesterol, sequestering it in a non-toxic manner that reverses EMT and restores drug sensitivity without causing muscle pains, hepato-renal toxicity, or neurocognitive decline associated with statin therapy

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the mechanism of cholesterol depletion from enzymatic inhibition (statins blocking HMG-CoA reductase) to physical sequestration (HPβCD forming inclusion complexes with cholesterol). This parameter change in the mode of action allows for effective cholesterol lowering and EMT reversal without the debilitating side effects of statin-mediated cholesterol synthesis inhibition

Inventive Principle:

Principle #35Parameter changes

2Reliability

If cholesterol synthesis is inhibited to restore drug sensitivity, then cancer cells become more sensitive to chemotherapy, but 30% of patient population display non-responsiveness and long-term impediment of cholesterol synthesis occurs

Engineering Contradiction:

Improvedrug sensitivityVSAvoidpatient responsiveness

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces HPβCD as an intermediary agent that mediates cholesterol depletion through inclusion complex formation rather than enzymatic inhibition. This intermediary approach bypasses the variability in patient response to statins and the adaptive resistance that develops over time, providing consistent cholesterol depletion and EMT reversal across diverse patient populations

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

Instead of inhibiting cholesterol synthesis enzymes (the conventional statin approach), the patent inverts the strategy by using HPβCD to bind and sequester existing cholesterol, thereby depleting cellular cholesterol stores through a相反 mechanism that avoids the limitations of enzymatic inhibition and improves patient responsiveness

Inventive Principle:

Principle #13The other way round (Inversion)

3Object-affected harmful factors

If cholesterol content is reduced to decrease membrane fluidity and cell motility, then metastatic potential is reduced, but existing cholesterol-lowering agents have limited efficacy due to side effects

Engineering Contradiction:

Improvemetastatic potentialVSAvoidtherapy effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent extracts cholesterol from cancer cells using HPβCD inclusion complexes, physically removing cholesterol from the cell membrane without requiring enzymatic inhibition. This extraction mechanism effectively decreases membrane fluidity and cell motility to reduce metastatic potential while avoiding the side effects that limit the effectiveness of conventional cholesterol-lowering agents

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

HPβCD effectively reverses the mesenchymal to epithelial phenotype, improving cancer therapy sensitivity, reducing metastasis, and minimizing side effects, while potentially lowering chemotherapy doses and relapse rates.

Implementation Method 1

2-hydroxypropyl-β-cyclodextrin (HPβCD) for use in a method of treating cancer, the method comprising administering the HPβCD in conjunction or combination with another cancer therapy

Methodology Applied

Scientific EffectInclusion complex formation: Solvation

Data Source

PatentUS20260034161A12-hydroxypropyl-beta-cyclodextrin as a cancer therapy neoadjuvant or adjuvant

Publication Date: 2026.02.05 UNIVERSITY OF THE WITWATERSRAND

AI summary

The invention relates to a compound, 2-hydroxypropyl-β-cyclodextrin (HPβCD), for use in methods of treating cancer, as well as to methods of treating a cancer using the compound HPβCD and to uses of the compound in the manufacture of one or more medicaments for the treatment of cancer. In particular, the compound HPβCD may be useful as an adjuvant or neoadjuvant therapy. Also provided, are pharmaceutical compositions comprising the HPβCD, optionally together with additional chemotherapeutic or cancer therapy agents.